RT Journal Article
SR Electronic
T1 Covid-19 impact on Parkinson’s Disease patients treated by drugs or deep brain stimulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.03.21252464
DO 10.1101/2021.03.03.21252464
A1 Salari, Mehri
A1 Etemadifar, Masoud
A1 Zali, Alireza
A1 Aminzade, Zahra
A1 Farsinejad, Parsa
A1 Fateh, Sepand Tehrani
YR 2021
UL http://medrxiv.org/content/early/2021/03/05/2021.03.03.21252464.abstract
AB Purpose Covid-19 has affected all people, especially those with chronic diseases, including Parkinson’s Disease (PD). Covid-19 may affect both motor and neuropsychiatric symptoms of PD patients. We intend to evaluate different aspects of Covid-19 impact on PD patients.Methods 647 PD patients were evaluated in terms of PD-related and Covid-19-related clinical presentations in addition to past medical history during the pandemic through an online questioner. They were compared with an age-matched control group consist of 673 individuals and a sample of the normal population consist of 1215 individuals.Results The prevalence of Covid-19 in PD patients was 11.28%. The mortality was 1.23% among PD patients. The prevalence of Covid-19 in PD patients who undergone DBS was 18.18%. No significant association was found between the duration of disease and the prevalence of Covid-19. A statistically significant higher prevalence of Covid-19 in PD patients who had direct contact with SARS-CoV-19 infected individuals was found. No statistically significant association has been found between the worsening of motor symptoms and Covid-19. PD patients and the normal population may differ in the prevalence of some psychological disorders, including anxiety and sleeping disorders, and Covid-19 may affect the psychological status.Conclusion PD patients possibly follow tighter preventive protocols, which lead to lower prevalence and severity of Covid-19 and its consequences in these patients. Although it seems Covid-19 does not affect motor and psychological aspects of PD as much as it was expected, more accurate evaluations are suggested in order to clarify such effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone of the authors have received any funding of any kind for either this project or other projects.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This cross sectional, case-control study approved by the Iran National Committee for Ethics in Biomedical Researches (IR.SBMU.RETECH.REC.1398.439)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data would be available on a request.